These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates. Khan M; Ma K; Wan I; Willcox MD Cont Lens Anterior Eye; 2023 Jun; 46(3):101819. PubMed ID: 36732125 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986 [TBL] [Abstract][Full Text] [Related]
9. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131 [TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
11. Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. Kowalski RP; Romanowski EG; Mah FS; Shanks RM; Gordon YJ Acta Ophthalmol; 2010 Jun; 88(4):e120-5. PubMed ID: 20456251 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates. Mei JA; Johnson W; Kinn B; Laskey E; Nolin L; Bhamare P; Stalker C; Dunman PM; Wozniak RAF Transl Vis Sci Technol; 2022 May; 11(5):26. PubMed ID: 35612831 [TBL] [Abstract][Full Text] [Related]
15. The In Vitro Evaluation of Tigecycline and the In Vivo Evaluation of RPX-978 (0.5% Tigecycline) as an Ocular Antibiotic. Romanowski EG; Kowalski TA; O'Connor KE; Yates KA; Mah FS; Shanks RM; Kowalski RP J Ocul Pharmacol Ther; 2016 Mar; 32(2):119-26. PubMed ID: 26545167 [TBL] [Abstract][Full Text] [Related]
16. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821 [TBL] [Abstract][Full Text] [Related]
17. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141 [TBL] [Abstract][Full Text] [Related]
18. Cefiderocol for treatment of an empyema due to extensively drug-resistant Kufel WD; Steele JM; Riddell SW; Jones Z; Shakeraneh P; Endy TP IDCases; 2020; 21():e00863. PubMed ID: 32577400 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis. Li SA; Liu J; Xiang Y; Wang YJ; Lee WH; Zhang Y Antimicrob Agents Chemother; 2014 Jun; 58(6):3144-50. PubMed ID: 24637683 [TBL] [Abstract][Full Text] [Related]
20. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. Satlin MJ; Simner PJ; Slover CM; Yamano Y; Nagata TD; Portsmouth S Antimicrob Agents Chemother; 2023 Jul; 67(7):e0019423. PubMed ID: 37347188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]